Latest news with #DavidPrice
South Wales Argus
5 hours ago
- Health
- South Wales Argus
Mounjaro could help obese people control asthma says study
The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. As an estimated 1.5 million people in the UK are now using weight loss drugs. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. 📢Important update Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025. ✅Around 1,000 people in Dorset will qualify under strict national criteria ✅No need to contact your doctor More: — NHS Dorset (@NHSDorset) June 23, 2025 After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. Recommended reading: 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.' Who is eligible for Mounjaro on the NHS? At the moment, the rules are very strict, and treatment is being rolled out gradually by NHS England. NICE has recommended tirzepatide (Mounjaro) for weight management for eligible adults living with obesity, who also present with other weight-related health problems, including: dyslipidaemia (abnormal fat levels in the blood) hypertension (high blood pressure) obstructive sleep apnoea (when your breathing stops and starts while you sleep) cardiovascular disease (heart and blood vessel disease) type 2 diabetes mellitus Speak to your doctor for more information.
BBC News
7 days ago
- Health
- BBC News
University of Aberdeen study says weight loss jabs may aid asthma
Weight loss injections could help to reduce asthma symptoms in obese people, according to researchers at the University of study by an international team of scientists found as well as the weight loss aspect, the drugs - called GLP-1s - also led to improved control of the respiratory analysed the medical records of more than 60,000 is hoped the injections could be used as a potential treatment in the future, as obese people are often resistant to steroids which are used to help control asthma. GLP-1s mimic a naturally-occurring hormone and help regulate blood sugar, insulin and control David Price from the University of Aberdeen said: "People with obesity and asthma are unique in that they are often resistant to steroid treatments."We know that GLP-1s work on inflammatory responses in the airways in a different way to traditionally used steroids."We found compelling evidence that GLP-1s, as well as increasing weight loss, also improved asthma symptoms."He said their findings suggested the drugs might have beneficial effects on asthma control for people with obesity and that should be "explored further". 'Promising alternative' Dr Erika Kennington, head of research and innovation at Asthma + Lung UK, said research had previously shown than people living with obesity who lost weight saw "improved control" of their said it was "encouraging" the study had shown that was still the case when using weight loss drugs."Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack," she said."So people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening."Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative."However, she said it was "too early to say" whether the drugs would be effective for people with asthma more widely."More research is needed to understand how these drugs actually improve asthma control," she added."Funding for lung health research is on life support and urgent action is needed to increase investment."
Daily Mirror
7 days ago
- Health
- Daily Mirror
Jabs like Mounjaro 'could help manage asthma for obese people'
Researchers said the drugs should be explored as a potential treatment for obese people with the respiratory condition, who are "often resistant" to steroids Injections used by those trying to lose weight could potentially alleviate asthma symptoms in obese people, a recent study suggests. The research indicates that these drugs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), should be considered as a potential treatment for obese people suffering from the respiratory condition, who are "often resistant" to steroids. These injections - originally developed as a treatment for type 2 diabetes - function by imitating the hormone GLP-1, which helps regulate blood sugar and insulin levels. Several variations of the drug are recommended by the NHS to combat obesity, including semaglutide, also known as Wegovy, and tirzepatide, or Mounjaro. Previous research has suggested that these drugs may significantly reduce the risk of diseases such as dementia and stroke. An international team of experts is currently investigating their potential impact on obese people with asthma, reports Bristol Live. Professor David Price, chair in primary care respiratory medicine at the University of Aberdeen, stated: "People with obesity and asthma are unique in that they are often resistant to steroid treatments. We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids." In the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs, and 50,555 people who were not on the drugs. Following a period of observation, the team discovered that those taking the injections lost more weight and had improved control over their asthma. Researchers have suggested that medical professionals "should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases". Prof Price stated: "We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. "In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further." Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, commented: "Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs." Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: "Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. "Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. "It's too early to say whether these drugs would be effective for people with asthma more widely. More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment."
Yahoo
7 days ago
- Health
- Yahoo
Weight-loss jabs could minimise the symptoms of asthma
Weight-loss jabs could help minimise asthma symptoms in obese people, according to a study. The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. READ MORE: Brits issued drink warning at popular Mediterranean holiday spot READ MORE: Gran banned from Asda after being accused of swapping yellow stickers 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'
Glasgow Times
7 days ago
- Health
- Glasgow Times
Mounjaro could help obese people control asthma says study
The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. As an estimated 1.5 million people in the UK are now using weight loss drugs. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. 📢Important update Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025. ✅Around 1,000 people in Dorset will qualify under strict national criteria ✅No need to contact your doctor More: — NHS Dorset (@NHSDorset) June 23, 2025 After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. Recommended reading: 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.' Who is eligible for Mounjaro on the NHS? At the moment, the rules are very strict, and treatment is being rolled out gradually by NHS England. NICE has recommended tirzepatide (Mounjaro) for weight management for eligible adults living with obesity, who also present with other weight-related health problems, including: dyslipidaemia (abnormal fat levels in the blood) hypertension (high blood pressure) obstructive sleep apnoea (when your breathing stops and starts while you sleep) cardiovascular disease (heart and blood vessel disease) type 2 diabetes mellitus Speak to your doctor for more information.
